new BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 213 hits with Last Name = 'stevens' and Initial = 'bd'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Glucagon receptor


(Homo sapiens (Human))
BDBM50360584
PNG
(CHEMBL1933350)
Show SMILES CCC[C@@H]([C@@H](c1c[nH]c2c(F)cc(C)cc12)c1ccc(Cl)cc1)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C30H30ClFN2O3/c1-3-4-23(19-5-7-21(8-6-19)30(37)33-14-13-27(35)36)28(20-9-11-22(31)12-10-20)25-17-34-29-24(25)15-18(2)16-26(29)32/h5-12,15-17,23,28,34H,3-4,13-14H2,1-2H3,(H,33,37)(H,35,36)/t23-,28+/m1/s1
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem

Patents

Article
PubMed
4n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2437
PNG
(US8507533, 157)
Show SMILES CC1(C)CC(C1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H27F3N6O3/c1-24(2)9-17(10-24)21(15-3-5-16(6-4-15)22(37)29-8-7-20(35)36)33-19-12-30-23(31-13-19)34-14-18(11-32-34)25(26,27)28/h3-6,11-14,17,21,33H,7-10H2,1-2H3,(H,29,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
5.55n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
5.75n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
7.60n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2390
PNG
(US8507533, 146)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 |r|
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
9.05n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50433595
PNG
(CHEMBL2381827)
Show SMILES CCCC(Nc1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H29F3N4O3/c1-4-5-22(18-6-8-19(9-7-18)25(36)30-11-10-23(34)35)32-21-12-16(2)24(17(3)13-21)33-15-20(14-31-33)26(27,28)29/h6-9,12-15,22,32H,4-5,10-11H2,1-3H3,(H,30,36)(H,34,35)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
12n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin


Bioorg Med Chem Lett 23: 3051-8 (2013)


Article DOI: 10.1016/j.bmcl.2013.03.014
BindingDB Entry DOI: 10.7270/Q27M099R
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50433577
PNG
(CHEMBL2381848)
Show SMILES CCC[C@H](Oc1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m0/s1
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
14n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin


Bioorg Med Chem Lett 23: 3051-8 (2013)


Article DOI: 10.1016/j.bmcl.2013.03.014
BindingDB Entry DOI: 10.7270/Q27M099R
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100806
PNG
(US8507533, 114 | US8507533, 115 | US8507533, 330)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-20-7-8-21(31-14-20)34-15-19(13-32-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
15.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360599
PNG
(CHEMBL1933365)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C26H27F3N4O3/c27-26(28,29)20-9-11-22(12-10-20)33-16-21(15-31-33)32-24(17-3-1-2-4-17)18-5-7-19(8-6-18)25(36)30-14-13-23(34)35/h5-12,15-17,24,32H,1-4,13-14H2,(H,30,36)(H,34,35)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
17n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100796
PNG
(US8507533, 101)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
17n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360599
PNG
(CHEMBL1933365)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C26H27F3N4O3/c27-26(28,29)20-9-11-22(12-10-20)33-16-21(15-31-33)32-24(17-3-1-2-4-17)18-5-7-19(8-6-18)25(36)30-14-13-23(34)35/h5-12,15-17,24,32H,1-4,13-14H2,(H,30,36)(H,34,35)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
17n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100827
PNG
(US8507533, 138 | US8507533, 151 | US8507533, 374)
Show SMILES Cc1cc(OC(C2CCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C27H28F3N3O4/c1-16-12-22(13-17(2)24(16)33-15-21(14-32-33)27(28,29)30)37-25(18-4-3-5-18)19-6-8-20(9-7-19)26(36)31-11-10-23(34)35/h6-9,12-15,18,25H,3-5,10-11H2,1-2H3,(H,31,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
20.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2376
PNG
(US8507533, 137)
Show SMILES CCC[C@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
20.2n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
25.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2391
PNG
(US8507533, 147)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)C1CCCCC1 |r|
Show InChI InChI=1S/C26H28F3N5O3/c27-26(28,29)20-14-32-34(16-20)22-11-10-21(15-31-22)33-24(17-4-2-1-3-5-17)18-6-8-19(9-7-18)25(37)30-13-12-23(35)36/h6-11,14-17,24,33H,1-5,12-13H2,(H,30,37)(H,35,36)/t24-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
26.7n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100850
PNG
(US8507533, 168)
Show SMILES CC(C)C[C@@H](Nc1ccc(cn1)C(=O)NCCC(O)=O)c1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F |r|
Show InChI InChI=1S/C26H30F3N5O3/c1-15(2)9-21(33-22-6-5-18(12-31-22)25(37)30-8-7-23(35)36)19-10-16(3)24(17(4)11-19)34-14-20(13-32-34)26(27,28)29/h5-6,10-15,21H,7-9H2,1-4H3,(H,30,37)(H,31,33)(H,35,36)/t21-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
27.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100852
PNG
(US8507533, 170 | US8507533, 419)
Show SMILES Cc1cc(cc(C)c1-n1cc(cn1)C(F)(F)F)C(Nc1ccc(cn1)C(=O)NCCC(O)=O)C1CCCC1
Show InChI InChI=1S/C27H30F3N5O3/c1-16-11-20(12-17(2)25(16)35-15-21(14-33-35)27(28,29)30)24(18-5-3-4-6-18)34-22-8-7-19(13-32-22)26(38)31-10-9-23(36)37/h7-8,11-15,18,24H,3-6,9-10H2,1-2H3,(H,31,38)(H,32,34)(H,36,37)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
28n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100844
PNG
(US8507533, 160 | US8507533, 398)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-25(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-24-13-14-26(30-18-24)33-19-23(17-31-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,25,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
29n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
29.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2241
PNG
(US8507533, 136)
Show SMILES CCC[C@@H](Nc1ccc(nc1)-n1cc(cn1)C(C)(C)C)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H33N5O3/c1-5-6-22(18-7-9-19(10-8-18)25(34)27-14-13-24(32)33)30-21-11-12-23(28-16-21)31-17-20(15-29-31)26(2,3)4/h7-12,15-17,22,30H,5-6,13-14H2,1-4H3,(H,27,34)(H,32,33)/t22-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
30.2n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100838
PNG
(US8507533, 153)
Show SMILES CCCC(Oc1cc(C)c(c(OC)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O5/c1-4-5-21(17-6-8-18(9-7-17)25(35)30-11-10-23(33)34)37-20-12-16(2)24(22(13-20)36-3)32-15-19(14-31-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
32.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2240
PNG
(US8507533, 135)
Show SMILES CC1(C)CC(C1)[C@H](Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)/t23-/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
35n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100837
PNG
(US8507533, 152)
Show SMILES Cc1cc(OC(C2CC(C)(C)C2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C29H32F3N3O4/c1-17-11-23(12-18(2)25(17)35-16-22(15-34-35)29(30,31)32)39-26(21-13-28(3,4)14-21)19-5-7-20(8-6-19)27(38)33-10-9-24(36)37/h5-8,11-12,15-16,21,26H,9-10,13-14H2,1-4H3,(H,33,38)(H,36,37)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
35.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100805
PNG
(US8507533, 113)
Show SMILES CCCC(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C22H23F3N6O3/c1-2-3-18(14-4-6-15(7-5-14)20(34)26-9-8-19(32)33)30-17-11-27-21(28-12-17)31-13-16(10-29-31)22(23,24)25/h4-7,10-13,18,30H,2-3,8-9H2,1H3,(H,26,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
38.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2438
PNG
(US8507533, 158)
Show SMILES CCOC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cc(cn1)C(F)(F)F)C1CC(C)(C)C1
Show InChI InChI=1S/C27H31F3N6O3/c1-4-39-22(37)9-10-31-24(38)18-7-5-17(6-8-18)23(19-11-26(2,3)12-19)35-21-14-32-25(33-15-21)36-16-20(13-34-36)27(28,29)30/h5-8,13-16,19,23,35H,4,9-12H2,1-3H3,(H,31,38)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
41n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100861
PNG
(US8507533, 188)
Show SMILES CC1(C)CC(C1)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N5O3/c1-25(2)11-18(12-25)23(16-3-5-17(6-4-16)24(37)30-10-9-22(35)36)33-19-7-8-21(31-13-19)34-14-20(32-15-34)26(27,28)29/h3-8,13-15,18,23,33H,9-12H2,1-2H3,(H,30,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
PDB
UniChem
US Patent
42.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100864
PNG
(US8507533, 193)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(Nc1cnc(nc1)-n1cnc(c1)C(F)(F)F)C1CCCC1
Show InChI InChI=1S/C24H25F3N6O3/c25-24(26,27)19-13-33(14-31-19)23-29-11-18(12-30-23)32-21(15-3-1-2-4-15)16-5-7-17(8-6-16)22(36)28-10-9-20(34)35/h5-8,11-15,21,32H,1-4,9-10H2,(H,28,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
44.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100815
PNG
(US8507533, 122)
Show SMILES CC(C)(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C28H35N5O3/c1-28(2,3)23-17-33(18-31-23)24-13-12-22(16-30-24)32-26(19-6-4-5-7-19)20-8-10-21(11-9-20)27(36)29-15-14-25(34)35/h8-13,16-19,26,32H,4-7,14-15H2,1-3H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
45.7n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100822
PNG
(US8507533, 129 | US8507533, 162 | US8507533, 399)
Show SMILES CCCC(Nc1ccc(nc1)-n1cnc(c1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H29N5O3/c1-2-6-24(21-9-11-22(12-10-21)28(36)29-16-15-27(34)35)32-23-13-14-26(30-17-23)33-18-25(31-19-33)20-7-4-3-5-8-20/h3-5,7-14,17-19,24,32H,2,6,15-16H2,1H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
47.3n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2229
PNG
(US8507533, 187 | US8507533, 448)
Show SMILES CCC[C@H](Oc1cc(C)c(c(C)c1)-n1cc2ccccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C29H31N3O4/c1-4-7-26(21-10-12-22(13-11-21)29(35)30-15-14-27(33)34)36-24-16-19(2)28(20(3)17-24)32-18-23-8-5-6-9-25(23)31-32/h5-6,8-13,16-18,26H,4,7,14-15H2,1-3H3,(H,30,35)(H,33,34)/t26-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
47.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360598
PNG
(CHEMBL1933364)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CCC(F)(F)F)Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F
Show InChI InChI=1S/C24H22F6N4O3/c25-23(26,27)11-9-20(15-1-3-16(4-2-15)22(37)31-12-10-21(35)36)33-18-13-32-34(14-18)19-7-5-17(6-8-19)24(28,29)30/h1-8,13-14,20,33H,9-12H2,(H,31,37)(H,35,36)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
48n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360598
PNG
(CHEMBL1933364)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CCC(F)(F)F)Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F
Show InChI InChI=1S/C24H22F6N4O3/c25-23(26,27)11-9-20(15-1-3-16(4-2-15)22(37)31-12-10-21(35)36)33-18-13-32-34(14-18)19-7-5-17(6-8-19)24(28,29)30/h1-8,13-14,20,33H,9-12H2,(H,31,37)(H,35,36)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
48n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100824
PNG
(US8507533, 131)
Show SMILES Cc1cc(OC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cc(C)c1-n1cnc(c1)C(F)(F)F
Show InChI InChI=1S/C28H30F3N3O4/c1-17-13-22(14-18(2)25(17)34-15-23(33-16-34)28(29,30)31)38-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(37)32-12-11-24(35)36/h7-10,13-16,19,26H,3-6,11-12H2,1-2H3,(H,32,37)(H,35,36)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
51n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100801
PNG
(US8507533, 109 | US8507533, 322)
Show SMILES CCCC(Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1F)C(=O)NCCC(O)=O
Show InChI InChI=1S/C23H23F4N5O3/c1-2-3-19(17-6-4-14(10-18(17)24)22(35)28-9-8-21(33)34)31-16-5-7-20(29-12-16)32-13-15(11-30-32)23(25,26)27/h4-7,10-13,19,31H,2-3,8-9H2,1H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
57.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM2387
PNG
(US8507533, 143)
Show SMILES CC(C)C[C@H](Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F)c1ccc(cn1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C23H25F3N6O3/c1-14(2)9-19(18-5-3-15(10-28-18)22(35)27-8-7-21(33)34)31-17-4-6-20(29-12-17)32-13-16(11-30-32)23(24,25)26/h3-6,10-14,19,31H,7-9H2,1-2H3,(H,27,35)(H,33,34)/t19-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
57.4n/an/an/an/an/an/an/an/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100826
PNG
(US8507533, 133)
Show SMILES CCCC(Oc1ccc(nc1)-n1cc(cn1)-c1ccccc1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H28N4O4/c1-2-6-25(21-9-11-22(12-10-21)28(35)29-16-15-27(33)34)36-24-13-14-26(30-18-24)32-19-23(17-31-32)20-7-4-3-5-8-20/h3-5,7-14,17-19,25H,2,6,15-16H2,1H3,(H,29,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
58n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100831
PNG
(US8507533, 144)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(cn1)C1CC1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C28H33N3O4/c1-4-5-25(21-8-10-22(11-9-21)28(34)29-13-12-26(32)33)35-24-14-18(2)27(19(3)15-24)31-17-23(16-30-31)20-6-7-20/h8-11,14-17,20,25H,4-7,12-13H2,1-3H3,(H,29,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
62.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100829
PNG
(US8507533, 140)
Show SMILES CCCC(Oc1ccc(cc1)-n1cc2cc(Cl)ccc2n1)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C27H26ClN3O4/c1-2-3-25(18-4-6-19(7-5-18)27(34)29-15-14-26(32)33)35-23-11-9-22(10-12-23)31-17-20-16-21(28)8-13-24(20)30-31/h4-13,16-17,25H,2-3,14-15H2,1H3,(H,29,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
62.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50433576
PNG
(CHEMBL2381849)
Show SMILES CCC[C@@H](Oc1cc(C)c(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O |r|
Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-22(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-21-12-16(2)24(17(3)13-21)32-15-20(14-31-32)26(27,28)29/h6-9,12-15,22H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)/t22-/m1/s1
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
64n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]-glucagon-cex from human glucagon receptor by cell based assay in presence of 0.2% bovine serum albumin


Bioorg Med Chem Lett 23: 3051-8 (2013)


Article DOI: 10.1016/j.bmcl.2013.03.014
BindingDB Entry DOI: 10.7270/Q27M099R
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100847
PNG
(US8507533, 163)
Show SMILES Cc1nn(cc1Cl)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C25H28ClN5O3/c1-16-21(26)15-31(30-16)22-11-10-20(14-28-22)29-24(17-4-2-3-5-17)18-6-8-19(9-7-18)25(34)27-13-12-23(32)33/h6-11,14-15,17,24,29H,2-5,12-13H2,1H3,(H,27,34)(H,32,33)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
65.9n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360597
PNG
(CHEMBL1933363)
Show SMILES CCCC(Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H25F3N4O3/c1-2-3-21(16-4-6-17(7-5-16)23(34)28-13-12-22(32)33)30-19-14-29-31(15-19)20-10-8-18(9-11-20)24(25,26)27/h4-11,14-15,21,30H,2-3,12-13H2,1H3,(H,28,34)(H,32,33)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
67n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360597
PNG
(CHEMBL1933363)
Show SMILES CCCC(Nc1cnn(c1)-c1ccc(cc1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H25F3N4O3/c1-2-3-21(16-4-6-17(7-5-16)23(34)28-13-12-22(32)33)30-19-14-29-31(15-19)20-10-8-18(9-11-20)24(25,26)27/h4-11,14-15,21,30H,2-3,12-13H2,1H3,(H,28,34)(H,32,33)
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
67n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Beta-1 adrenergic receptor


(Homo sapiens (Human))
BDBM50174271
PNG
(4-(piperazin-1-yl)-1H-indole | CHEMBL200234)
Show SMILES C1CN(CCN1)c1cccc2[nH]ccc12
Show InChI InChI=1S/C12H15N3/c1-2-11-10(4-5-14-11)12(3-1)15-8-6-13-7-9-15/h1-5,13-14H,6-9H2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
MMDB
PC cid
PC sid
PDB
UniChem

Patents

Article
PubMed
68n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Binding affinity to beta1 adrenergic receptor (unknown origin)


J Med Chem 56: 3444-5 (2013)


Article DOI: 10.1021/jm400561w
BindingDB Entry DOI: 10.7270/Q23N24RC
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100797
PNG
(US8507533, 105)
Show SMILES CC(C)CC(Nc1cnc(c(C)c1)-n1cc(cn1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C25H28F3N5O3/c1-15(2)10-21(17-4-6-18(7-5-17)24(36)29-9-8-22(34)35)32-20-11-16(3)23(30-13-20)33-14-19(12-31-33)25(26,27)28/h4-7,11-15,21,32H,8-10H2,1-3H3,(H,29,36)(H,34,35)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
69.8n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50360601
PNG
(CHEMBL1933349)
Show SMILES COc1ccc2cc(ccc2c1)-c1cc(nn1[C@@H](C)c1ccc(cc1)C(=O)NCCC(O)=O)-c1cc(Cl)cc(Cl)c1 |r|
Show InChI InChI=1S/C32H27Cl2N3O4/c1-19(20-3-5-21(6-4-20)32(40)35-12-11-31(38)39)37-30(18-29(36-37)25-14-26(33)17-27(34)15-25)24-8-7-23-16-28(41-2)10-9-22(23)13-24/h3-10,13-19H,11-12H2,1-2H3,(H,35,40)(H,38,39)/t19-/m0/s1
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
Purchase

CHEMBL
PC cid
PC sid
PDB
UniChem

Patents

PDB
Article
PubMed
70n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
3D
3D Structure (crystal)
Glucagon


(Homo sapiens (Human))
BDBM100799
PNG
(US8507533, 107)
Show SMILES OC(=O)CCNC(=O)c1ccc(cc1)C(CC1CC1)Nc1ccc(nc1)-n1cc(cn1)C(F)(F)F
Show InChI InChI=1S/C24H24F3N5O3/c25-24(26,27)18-12-30-32(14-18)21-8-7-19(13-29-21)31-20(11-15-1-2-15)16-3-5-17(6-4-16)23(35)28-10-9-22(33)34/h3-8,12-15,20,31H,1-2,9-11H2,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
71.6n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon receptor


(Homo sapiens (Human))
BDBM50244455
PNG
((R)-3-{4-[1-(4-Cyclohex-1-enylphenyl)-3-(3,5-dichl...)
Show SMILES O[C@H](CNC(=O)c1ccc(CN(C(=O)Nc2cc(Cl)cc(Cl)c2)c2ccc(cc2)C2=CCCCC2)cc1)C(O)=O |r,t:31|
Show InChI InChI=1S/C30H29Cl2N3O5/c31-23-14-24(32)16-25(15-23)34-30(40)35(26-12-10-21(11-13-26)20-4-2-1-3-5-20)18-19-6-8-22(9-7-19)28(37)33-17-27(36)29(38)39/h4,6-16,27,36H,1-3,5,17-18H2,(H,33,37)(H,34,40)(H,38,39)/t27-/m1/s1
PDB
MMDB

UniProtKB/SwissProt

B.MOAD
antibodypedia
GoogleScholar
AffyNet 
CHEMBL
KEGG
PC cid
PC sid
UniChem

Patents

Article
PubMed
85n/an/an/an/an/an/an/an/a



Pfizer Inc.

Curated by ChEMBL


Assay Description
Displacement of [125I]Glucagon-Cex from human GCGR


Bioorg Med Chem Lett 22: 415-20 (2011)


Article DOI: 10.1016/j.bmcl.2011.10.113
BindingDB Entry DOI: 10.7270/Q2H70G82
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100856
PNG
(US8507533, 181)
Show SMILES CC(C)(C)C(Nc1ccc(nc1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C24H26F3N5O3/c1-23(2,3)21(15-4-6-16(7-5-15)22(35)28-11-10-20(33)34)31-17-8-9-19(29-12-17)32-13-18(30-14-32)24(25,26)27/h4-9,12-14,21,31H,10-11H2,1-3H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
87.2n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100816
PNG
(US8507533, 123)
Show SMILES CC(C)c1cn(cn1)-c1ccc(NC(C2CCCC2)c2ccc(cc2)C(=O)NCCC(O)=O)cn1
Show InChI InChI=1S/C27H33N5O3/c1-18(2)23-16-32(17-30-23)24-12-11-22(15-29-24)31-26(19-5-3-4-6-19)20-7-9-21(10-8-20)27(35)28-14-13-25(33)34/h7-12,15-19,26,31H,3-6,13-14H2,1-2H3,(H,28,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
88.4n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Glucagon


(Homo sapiens (Human))
BDBM100830
PNG
(US8507533, 141)
Show SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cnc(c1)C(F)(F)F)c1ccc(cc1)C(=O)NCCC(O)=O
Show InChI InChI=1S/C26H28F3N3O4/c1-4-5-21(18-6-8-19(9-7-18)25(35)30-11-10-23(33)34)36-20-12-16(2)24(17(3)13-20)32-14-22(31-15-32)26(27,28)29/h6-9,12-15,21H,4-5,10-11H2,1-3H3,(H,30,35)(H,33,34)
Reactome pathway
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
89.5n/an/an/an/an/an/a7.4n/a



Pfizer Inc.

US Patent


Assay Description
The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.


US Patent US8507533 (2013)


BindingDB Entry DOI: 10.7270/Q23R0RGH
More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 213 total )  |  Next  |  Last  >>
Jump to: